Regulators Call for More Harmonization On Ultra-Rare ATMPs
Early discussions between companies and multiple regulators could drive greater alignment among jurisdictions.
You may also be interested in...
England’s Innovative Medicines Fund is aimed at providing earlier access to promising new treatments, including gene therapies, when further data is needed for routine commissioning.
England’s health technology assessment body NICE did not recover costs for technology appraisals through fees thanks to the COVID-19 pandemic.
Reimbursement timelines in Italy and France for the treatments in question have been quicker than the average.